A Phase 3 interventional study of Efgartigimod PH20 SC and Placebo PH20 SC in Myasthenia Gravis, Ocular, sponsored by argenx. Active, not recruiting at 102 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by argenx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one is the 4th largest by enrollment, is one of 5 that started in 2024, is one of 10 in phase 3, reaches primary completion later than 3 of the 13 other live ones, and was the 11th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.
Browse Myasthenia Gravis studies →11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:
argenx · Sites in United States, Belgium, Germany and 5 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 65+
argenx · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 18+
Clinique Neuro-Outaouais · Sites in Canada
Ages 18–80
By country, each count listing its studies:
efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 12 · Phase 4 4
First in 2016; this study’s year is marked. 5 started in 2024.
This study's enrollment of 141 is above the median of 44 across 217 interventional studies indexed under Myasthenia Gravis.
Median enrollment 55 across the 20 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 8 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
18 studies in Myasthenia Gravis by argenx: 9 open now, 12 under way, 5 of them phase 3. Of 6 finished, 6 (100%) have results posted.
Among the 18 studies in Myasthenia Gravis by argenx, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2024, is one of 7 in phase 3, reaches primary completion later than 1 of the 11 other live ones, and was the 13th registered.
argenx’s Myasthenia Gravis studies by the year they started, since 2016.
7 of the studies testing efgartigimod alfa in Myasthenia Gravis that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06765161Phase 3Clinique Neuro-OutaouaisEfgartigimod in IVIG Dependent Myasthenia Gravis Patients | 2027-01-06 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT07231523Phase 3Shanghai Zhongshan HospitalEFG vs IVIG in TAMG | 2027-06-01 |
| NCT06392386Phase 3argenxA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | 2027-09 |
| NCT06221501Shanghai Zhongshan HospitalPerioperative Efgartigimod for Thymoma and Myasthenia Gravis | 2026-12-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among argenx’s 18 in Myasthenia Gravis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 years). In part A, half of the participants will receive efgartigimod PH20 SC and the other half will receive placebo. In part B, all participants will receive efgartigimod PH20 SC. The participants will be in the study for about up to 2 years and 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving efgartigimod PH20 SC during part A and part B
Combination Product: Efgartigimod PH20 SC
Participants receiving placebo PH20 SC in Part A and Efgartigimod PH20 SC in Part B
Combination Product: Efgartigimod PH20 SC · Other: Placebo PH20 SC
Drug pages: Efgartigimod alfa · Hyaluronidase (human recombinant)
Subcutaneous efgartigimod PH20 SC given by prefilled syringe
Subcutaneous placebo PH20 SC given by prefilled syringe
MGII (PRO) ocular score change from baseline to day 29 in part A
The Myasthenia Gravis Impairment Index (MGII) is a scoring tool measuring disease severity. It consists of 22 patient-reported outcomes (PRO) and 6 physical examinations (PE). The Ocular PRO score varies between 0 and 18. The higher the score, the more severe the disease.
Time frame: Up to 29 days
MGII (PRO+PE) ocular score change from baseline to day 29 in part A
The Myasthenia Gravis Impairment Index (MGII) is a scoring tool measuring disease severity. It consists of 22 patient-reported outcomes (PRO) and 6 physical examinations (PE). The Ocular PRO score varies between 0 and 18. The ocular PE score varies between 0 and 5. The higher the score, the more severe the disease.
Time frame: Up to 29 days
MG-ADL ocular domain score change from baseline to day 29 in part A
The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale assesses MG symptoms and their effects on daily activities. The ocular score varies between 0 and 16 (with 16 the most severe).
Time frame: Up to 29 days
MGII total score change from baseline to day 29 in part A
The Myasthenia Gravis Impairment Index (MGII) is a scoring tool measuring disease severity. It consists of 22 patient-reported outcomes (PRO) and 6 physical examinations (PE). The score varies between 0 and 84. The higher the score, the more severe the disease.
Time frame: Up to 29 days
MGII (PE) ocular score change from baseline to day 29 in part A
The Myasthenia Gravis Impairment Index (MGII) is a scoring tool measuring disease severity. It consists of 6 physical examinations (PE). The score varies between 0 and 5. The higher the score, the more severe the disease.
Time frame: Up to 29 days
MG-ADL total score change from baseline to day 29 in part A
The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale assesses MG symptoms and their effects on daily activities. The score varies between 0 and 24 (with 24 the most severe).
Time frame: Up to 29 days
MGII ocular scores changes (PRO) from baseline in part A+B
The Myasthenia Gravis Impairment Index (MGII) is a scoring tool measuring disease severity. It consists of 22 patient-reported outcomes (PRO) and 6 physical examinations (PE). The Ocular PRO score varies between 0 and 18. The ocular PE score varies between 0 and 5. The higher the score, the more severe the disease.
Time frame: Up to 111 weeks
Incidence of (serious) adverse events
Time frame: Up to 111 weeks
MG-QoL15r total score changes from baseline in part A+B
The Myasthenia Gravis Quality of Life 15-item scale revised (MG-QoL15r) questionnaire is a patient-reported instrument that measures the impact of MG symptoms on Quality of Life. The score varies between 0 and 30 (with 30 the lowest quality of life).
Time frame: Up to 111 weeks
NEI VFQ-25 score changes from baseline in part A+B
The 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) is a 25-item vision-targeted questionnaire. The score varies between 0 and 100 (with 0 being the worst score)
Time frame: Up to 111 weeks
Percent change from baseline in total IgG levels over time in part A+B
Time frame: Up to 111 weeks
Percent change from baseline in AChR-Ab levels in AChR-Ab seropositive participants over time in part A+B
Time frame: Up to 111 weeks
Incidence of Anti-Drug Antibodies and Neutralizing Antibodies against efgartigimod in part A+B
Time frame: Up to 111 weeks
Incidence of antibodies and Neutralizing Antibodies against rHuPH20 in part A+B
Time frame: Up to 111 weeks
Showing the first 100 of 102 sites across 25 countries. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2024 to primary completion in Jan 2026, 15 months.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 15 months is below that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)